D
Douglas J. Loftus
Researcher at National Institutes of Health
Publications - 21
Citations - 1607
Douglas J. Loftus is an academic researcher from National Institutes of Health. The author has contributed to research in topics: T cell & Antigen. The author has an hindex of 14, co-authored 21 publications receiving 1567 citations.
Papers
More filters
Journal ArticleDOI
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.
Paul F. Robbins,Mona El-Gamil,Yong F. Li,Yutaka Kawakami,Douglas J. Loftus,Ettore Appella,Steven A. Rosenberg +6 more
TL;DR: The isolation of a cDNA clone encoding beta- catenin was reported, which was shown to be recognized by the tumor-infiltrating lymphocyte (TIL) 1290, a HLA-A24 restricted melanoma-specific CTL line from patient 888, indicating that this represented a unique mutation in this patient's melanoma.
Journal ArticleDOI
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1((27-35))
Douglas J. Loftus,Chiara Castelli,Timothy M. Clay,Paola Squarcina,Francesco M. Marincola,Michael I. Nishimura,Giorgio Parmiani,Ettore Appella,Licia Rivoltini +8 more
TL;DR: In this paper, a protein database search for potential MART-1 epitope mimics was done using criteria developed from analyses of effector recognition of singly substituted peptide analogues of MART27-35.
Journal ArticleDOI
Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)
Michael L. Salgaller,Patricia A. Lodge,Joanne G. McLean,Ben A. Tjoa,Douglas J. Loftus,Haakon Ragde,G.M. Kenny,Mary Rogers,Alton L. Boynton,Gerald P. Murphy +9 more
TL;DR: The program for the immune monitoring of phase II participants given dendritic cell (DC)/prostate‐specific membrane antigen (PSMA)‐based immunotherapy, and some initial findings are presented.
Journal Article
A Superagonist Variant of Peptide MART1/Melan A27–35 Elicits Anti-Melanoma CD8+ T Cells with Enhanced Functional Characteristics: Implication for More Effective Immunotherapy
Licia Rivoltini,Paola Squarcina,Douglas J. Loftus,Chiara Castelli,Paolo Tarsini,Arabella Mazzocchi,Francesca Rini,Vincenzo Viggiano,Filiberto Belli,Giorgio Parmiani +9 more
TL;DR: In this article, a singly substituted peptide derived from the epitope MART127-35 and containing a Leu in position 1 (LAGIGILTV; 1L) behaves as a superagonist by in vitro inducing specific T cells with enhanced immunological functions.
Journal ArticleDOI
The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.
Thomas K. Hoffmann,Douglas J. Loftus,Koji Nakano,Markus Maeurer,Kazuaki Chikamatsu,Ettore Appella,Theresa L. Whiteside,Albert B. DeLeo +7 more
TL;DR: The use of variant peptides of the wt p53264–272 epitope represents a promising approach to overcoming the nonresponsiveness of certain cancer patients to this self epitope, thereby enhancing its potential use in tumor vaccines for appropriately selected cancer patients.